pyrazines has been researched along with Carcinoma, Medullary in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Masmiquel Comas, L; Nicolau Ramis, J | 1 |
Ain, KB; Fanourakis, G; Kotoula, V; McMillin, D; McMullan, C; Mitsiades, CS; Mitsiades, N; Negri, J; Poulaki, V; Tseleni-Balafouta, S | 1 |
Delmore, JE; Hayden, P; Kotoula, V; McMillin, DW; McMullan, C; Mitsiades, CS; Mitsiades, N; Negri, J; Poulaki, V | 1 |
3 other study(ies) available for pyrazines and Carcinoma, Medullary
Article | Year |
---|---|
[The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].
Topics: Animals; Breast Neoplasms; Calcitonin; Carcinoma, Medullary; Clinical Trials as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Disease Susceptibility; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Infections; Liraglutide; Pancreatitis; Pharmacovigilance; Pioglitazone; Pyrazines; Risk Assessment; Safety-Based Drug Withdrawals; Sitagliptin Phosphate; Species Specificity; Thiazolidinediones; Thyroid Neoplasms; Triazoles; Urinary Bladder Neoplasms | 2012 |
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Medullary; Caspases; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Doxorubicin; Enzyme Inhibitors; Humans; Insulin-Like Growth Factor I; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Proto-Oncogene Proteins c-jun; Pyrazines; Thyroid Neoplasms; Tumor Suppressor Protein p53 | 2006 |
Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; BH3 Interacting Domain Death Agonist Protein; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Medullary; Cell Line, Tumor; Colorimetry; Doxorubicin; Genes, bcl-2; Humans; Membrane Potentials; Oncogene Protein v-akt; Protease Inhibitors; Pyrazines; RNA, Neoplasm; Tetrazolium Salts; Thiazoles; Thyroid Neoplasms; Transcription, Genetic | 2007 |